Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206
Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.
Read original at benzingaStocks · News reference
Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270
Cantor Fitzgerald analyst Steve Seedhouse maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $266 to $270.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 11:03 AM
- Checked
- Aug 14, 2026, 11:03 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Full Transcript: Belite Bio Q2 2026 Earnings Call
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For
Read original at benzingaBelite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) Estimate
Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.79) by 31.65 percent. This is a 8 percent decrease over losses of $(0.50) per share from the same
Read original at benzinga